vs
HERON THERAPEUTICS, INC.（HRTX）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
HERON THERAPEUTICS, INC.的季度营收约是RBB Bancorp的1.3倍（$40.6M vs $32.3M），RBB Bancorp净利率更高（31.5% vs -7.3%，领先38.8%），RBB Bancorp同比增速更快（12.6% vs -0.5%），过去两年HERON THERAPEUTICS, INC.的营收复合增速更高（8.2% vs 7.0%）
安提贝制药是一家总部位于多伦多的制药企业，由曾参与创立全球首个气态介质药物开发企业NicOx的约翰·L·华莱士创立于2009年。该企业专注于依托气态介质技术研发缓解疼痛与炎症的药物，2013年在多伦多风险交易所挂牌，2015年收购再生医学领域经销商Citagenix，2020年11月转板多伦多证券交易所。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
HRTX vs RBB — 直观对比
营收规模更大
HRTX
是对方的1.3倍
$32.3M
营收增速更快
RBB
高出13.0%
-0.5%
净利率更高
RBB
高出38.8%
-7.3%
两年增速更快
HRTX
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $40.6M | $32.3M |
| 净利润 | $-3.0M | $10.2M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 0.1% | 39.5% |
| 净利率 | -7.3% | 31.5% |
| 营收同比 | -0.5% | 12.6% |
| 净利润同比 | -180.6% | 132.1% |
| 每股收益（稀释后） | $-0.01 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRTXRBB
| Q4 25 | $40.6M | $32.3M | ||
| Q3 25 | $38.2M | $32.6M | ||
| Q2 25 | $37.2M | $35.8M | ||
| Q1 25 | $38.9M | $28.5M | ||
| Q4 24 | $40.8M | $28.7M | ||
| Q3 24 | $32.8M | $30.3M | ||
| Q2 24 | $36.0M | $27.5M | ||
| Q1 24 | $34.7M | $28.2M |
净利润HRTXRBB
| Q4 25 | $-3.0M | $10.2M | ||
| Q3 25 | $-17.5M | $10.1M | ||
| Q2 25 | $-2.4M | $9.3M | ||
| Q1 25 | $2.6M | $2.3M | ||
| Q4 24 | $3.7M | $4.4M | ||
| Q3 24 | $-4.8M | $7.0M | ||
| Q2 24 | $-9.2M | $7.2M | ||
| Q1 24 | $-3.2M | $8.0M |
毛利率HRTXRBB
| Q4 25 | 72.6% | — | ||
| Q3 25 | 68.8% | — | ||
| Q2 25 | 73.5% | — | ||
| Q1 25 | 78.3% | — | ||
| Q4 24 | 74.9% | — | ||
| Q3 24 | 71.2% | — | ||
| Q2 24 | 70.8% | — | ||
| Q1 24 | 75.6% | — |
营业利润率HRTXRBB
| Q4 25 | 0.1% | 39.5% | ||
| Q3 25 | -10.7% | 40.7% | ||
| Q2 25 | -4.4% | 36.1% | ||
| Q1 25 | 8.1% | 11.2% | ||
| Q4 24 | 10.2% | 17.6% | ||
| Q3 24 | -13.6% | 31.6% | ||
| Q2 24 | -17.9% | 35.6% | ||
| Q1 24 | -13.8% | 39.9% |
净利率HRTXRBB
| Q4 25 | -7.3% | 31.5% | ||
| Q3 25 | -45.8% | 31.2% | ||
| Q2 25 | -6.4% | 26.1% | ||
| Q1 25 | 6.8% | 8.0% | ||
| Q4 24 | 9.0% | 15.3% | ||
| Q3 24 | -14.8% | 23.1% | ||
| Q2 24 | -25.6% | 26.4% | ||
| Q1 24 | -9.1% | 28.4% |
每股收益（稀释后）HRTXRBB
| Q4 25 | $-0.01 | $0.59 | ||
| Q3 25 | $-0.10 | $0.59 | ||
| Q2 25 | $-0.02 | $0.52 | ||
| Q1 25 | $0.01 | $0.13 | ||
| Q4 24 | $0.02 | $0.26 | ||
| Q3 24 | $-0.03 | $0.39 | ||
| Q2 24 | $-0.06 | $0.39 | ||
| Q1 24 | $-0.02 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.6M | $212.3M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | $14.3M | $523.4M |
| 总资产 | $255.9M | $4.2B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资HRTXRBB
| Q4 25 | $28.6M | $212.3M | ||
| Q3 25 | $43.1M | $234.9M | ||
| Q2 25 | $16.5M | $191.9M | ||
| Q1 25 | $19.3M | $238.8M | ||
| Q4 24 | $25.8M | $257.7M | ||
| Q3 24 | $25.7M | $349.4M | ||
| Q2 24 | $18.4M | $252.8M | ||
| Q1 24 | $20.4M | — |
总债务HRTXRBB
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.8M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $119.6M | ||
| Q4 24 | — | $119.5M | ||
| Q3 24 | — | $119.4M | ||
| Q2 24 | — | $119.3M | ||
| Q1 24 | — | $119.2M |
股东权益HRTXRBB
| Q4 25 | $14.3M | $523.4M | ||
| Q3 25 | $14.9M | $514.3M | ||
| Q2 25 | $-27.3M | $517.7M | ||
| Q1 25 | $-28.5M | $510.3M | ||
| Q4 24 | $-33.7M | $507.9M | ||
| Q3 24 | $-40.0M | $509.7M | ||
| Q2 24 | $-37.9M | $511.3M | ||
| Q1 24 | $-33.8M | $514.0M |
总资产HRTXRBB
| Q4 25 | $255.9M | $4.2B | ||
| Q3 25 | $248.9M | $4.2B | ||
| Q2 25 | $232.1M | $4.1B | ||
| Q1 25 | $235.8M | $4.0B | ||
| Q4 24 | $233.1M | $4.0B | ||
| Q3 24 | $220.8M | $4.0B | ||
| Q2 24 | $218.1M | $3.9B | ||
| Q1 24 | $217.9M | $3.9B |
负债/权益比HRTXRBB
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.2M | $43.4M |
| 自由现金流经营现金流 - 资本支出 | — | $42.6M |
| 自由现金流率自由现金流/营收 | — | 131.8% |
| 资本支出强度资本支出/营收 | 0.0% | 2.5% |
| 现金转化率经营现金流/净利润 | — | 4.26× |
| 过去12个月自由现金流最近4个季度 | — | $73.5M |
8季度趋势，按日历期对齐
经营现金流HRTXRBB
| Q4 25 | $-9.2M | $43.4M | ||
| Q3 25 | $1.3M | $2.1M | ||
| Q2 25 | $-10.9M | $21.7M | ||
| Q1 25 | $-8.9M | $7.8M | ||
| Q4 24 | $-11.8M | $58.5M | ||
| Q3 24 | $3.4M | $24.5M | ||
| Q2 24 | $-4.6M | $11.7M | ||
| Q1 24 | $-9.5M | $4.8M |
自由现金流HRTXRBB
| Q4 25 | — | $42.6M | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | $-11.1M | $21.6M | ||
| Q1 25 | $-9.0M | $7.6M | ||
| Q4 24 | — | $57.7M | ||
| Q3 24 | $2.9M | $24.2M | ||
| Q2 24 | — | $11.5M | ||
| Q1 24 | — | $4.7M |
自由现金流率HRTXRBB
| Q4 25 | — | 131.8% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | -29.8% | 60.2% | ||
| Q1 25 | -23.1% | 26.7% | ||
| Q4 24 | — | 201.0% | ||
| Q3 24 | 9.0% | 80.0% | ||
| Q2 24 | — | 42.0% | ||
| Q1 24 | — | 16.6% |
资本支出强度HRTXRBB
| Q4 25 | 0.0% | 2.5% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.6% | 0.3% | ||
| Q1 25 | 0.3% | 0.6% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | 1.3% | 0.8% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.5% |
现金转化率HRTXRBB
| Q4 25 | — | 4.26× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | -3.37× | 3.39× | ||
| Q4 24 | -3.22× | 13.34× | ||
| Q3 24 | — | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HRTX
| CINVANTI | $22.9M | 56% |
| ZYNRELEF | $12.5M | 31% |
| Aponvie | $3.8M | 9% |
| SUSTOL | $1.3M | 3% |
RBB
暂无分部数据
